Kurs kaydını izlemek için tıklayınız.

• 3. Modül Programı
• Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
• A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
• Acute myelogenous leukemia in adolescents and young adults
• Acute myeloid leukaemia in adult patients- ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
• Acute Myeloid Leukemia in Children- Emerging Paradigms in Genetics and New Approaches to Therapy
• Acute myeloid leukemia Treatment and research outlook for 2021 and the MD Anderson approach
• Acute promyelocytic leukemia current treatment algorithms
• Acute Promyelocytic Leukemia in Children
• Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy
• American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
• Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia
• Recent advances in the understanding and treatment of acute myeloid leukemia [version 1; referees: 3 approved]
• An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
• Management of patients with acute promyelocytic leukemia
• Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia- registry results from the European LeukemiaNet
• Genetic aberrations involved in relapse of pediatric acute myeloid leukemia: A literature review
• Molecular Genetics of Pediatric Acute Myeloid Leukemia
• American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
• Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia
• Treatments for children and adolescents with AML
• Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group
• Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience
• Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children’s Oncology Group Trial AAML0531
• How I treat pediatric acute myeloid leukemia
• What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort
• Overexpression of CD200 and CD123 is a major influential factor
• Pediatric relapsed acute myeloid leukemia_ a systematic review
• Pediatric acute myeloid leukemia updates on biology, risk stratification, and therapy
• Pediatric acute myeloid leukemia_ updates on biology, risk stratification, and therapy
• Pediatric APL Gelişmeler
• Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
• Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
• Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy
• Allogeneic transplantation in primary refractory AML
• Relapsed or primary refractory AML: moving past MEC and FLAG-ida
• Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
• Second Relapse of Pediatric Patients with AML
• Sequential therapy for patients with primary refractory acute myeloid leukemia a historical prospective analysis of the German and Israeli experience
• Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
• Advances in Pediatric Acute Promyelocytic Leukemia
• Systematic review of epigenetic targets
• Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia- a phase 1, dose-escalation study
• Wilms Tumor 1 Mutations Are Independent Poor Prognostic Factors
• Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation
• Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia